Neil Bhowmick - 08 Oct 2025 Form 4 Insider Report for Kairos Pharma, LTD. (KAPA)

Reporting relationship: Chief Scientific Officer
Issuer ticker: KAPA
Reported as of: 08 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Dec 2025, 16:10:14 UTC
Prior SEC filing: 07 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Neil Bhowmick

Key filing fact

Neil Bhowmick filed Form 4 for Kairos Pharma, LTD. (KAPA) on 30 Dec 2025.

Key facts

This page summarizes Neil Bhowmick's Form 4 filing for Kairos Pharma, LTD. (KAPA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Dec 2025, 16:10.

Change

Previous filing in this sequence was filed on 07 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001872210 Primary reporting owner

Bhowmick Neil

Relationship: Chief Scientific Officer
Address: C/O KAIROS PHARMA, LTD., 2355 WESTWOOD BLVD, #139, LOS ANGELES
Signature: /s/ Neil Bhowmick
Signature date: 30 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KAPA transaction

COMMON STOCK

Award

Transaction value: $0
Shares: +171,756
Change %: +15%
Price: $0.000000
Shares after: 1,311,739
Date: 08 Oct 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents 171,756 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 171,756 RSUs are scheduled to vest on the on the first anniversary of the grant date which is October 8, 2026.

Footnote F2

Consists of (1) 1,135,317 shares of common stock and (2) 176,422 RSUs which remain subject to vesting.